- Home
- ONVO vs CDT Comparison
ONVO vs CDT Comparison
Compare ONVO & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONVO
- CDT
- Stock Information
- Founded
- ONVO 2007
- CDT 2019
- Country
- ONVO United States
- CDT United States
- Employees
- ONVO N/A
- CDT N/A
- Industry
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- ONVO Health Care
- CDT Health Care
- Exchange
- ONVO Nasdaq
- CDT Nasdaq
- Market Cap
- ONVO 6.5M
- CDT 7.1M
- IPO Year
- ONVO N/A
- CDT N/A
- Fundamental
- Price
- ONVO $0.39
- CDT $0.07
- Analyst Decision
- ONVO
- CDT
- Analyst Count
- ONVO 0
- CDT 0
- Target Price
- ONVO N/A
- CDT N/A
- AVG Volume (30 Days)
- ONVO 243.5K
- CDT 101.0M
- Earning Date
- ONVO 02-06-2025
- CDT 02-14-2025
- Dividend Yield
- ONVO N/A
- CDT N/A
- EPS Growth
- ONVO N/A
- CDT N/A
- EPS
- ONVO N/A
- CDT N/A
- Revenue
- ONVO $103,000.00
- CDT N/A
- Revenue This Year
- ONVO $59.08
- CDT N/A
- Revenue Next Year
- ONVO $18.24
- CDT N/A
- P/E Ratio
- ONVO N/A
- CDT N/A
- Revenue Growth
- ONVO N/A
- CDT N/A
- 52 Week Low
- ONVO $0.32
- CDT $0.05
- 52 Week High
- ONVO $1.74
- CDT $3.92
- Technical
- Relative Strength Index (RSI)
- ONVO 47.81
- CDT 45.83
- Support Level
- ONVO $0.34
- CDT $0.08
- Resistance Level
- ONVO $0.51
- CDT $0.18
- Average True Range (ATR)
- ONVO 0.06
- CDT 0.02
- MACD
- ONVO -0.00
- CDT 0.00
- Stochastic Oscillator
- ONVO 30.00
- CDT 11.90
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.